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Abstract—The term “In Silico Trial” indicates the use of 
computer modelling and simulation to evaluate the safety 
and efficacy of a medical product, whether a drug, a medical 
device, a diagnostic product or an advanced therapy 
medicinal product.  Predictive models are positioned as 
new methodologies for the development and the regulatory 
evaluation of medical products.  New methodologies are 
qualified by regulators such as FDA and EMA through 
formal processes, where a first step is the definition of the 
Context of Use (CoU), which is a concise description of how 
the new methodology is intended to be used in the 
development and regulatory assessment process. As In 
Silico Trials are a disruptively innovative class of new 
methodologies, it is important to have a list of possible 
CoUs highlighting potential applications for the 
development of the relative regulatory science.  This review 
paper presents the result of a consensus process that took 
place in the InSilicoWorld Community of Practice, an online 
forum for experts in in silico medicine. The experts involved 
identified 46 descriptions of possible CoUs which were 
organised into a candidate taxonomy of nine CoU 
categories. Examples of 31 CoUs were identified in the 





Manuscript submitted on March 27th, 2021. This work was supported 
in part by the STriTuVaD project (H2020-SC1-2017-CNECT-2/777123), 
the CompBioMed2 project (H2020-INFRAEDI-2018-1/823712) and 
InSilicoWorld project (H2020-SC1-DTH-2020-1/101016503). 
 
M. V. is with the Department of Industrial Engineering, Alma Mater 
Studiorum - University of Bologna, 40136 Bologna IT and the Medical 
Technology Lab, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna IT 
(e-mail: marco.viceconti@unibo.it). 
L. E. is with the In Silico Trials Technologies, Via Parini, 9 - 20121 
Milano IT (e-mail: luca.emili@insilicotrials.com). 
P. A. is with DePuy Synthes Spine, Johnson and Johnson, Raynham, 
MA, United States (e-mail: pafshari@its.jnj.com). 
E. C. is with Novadiscovery SAS, Lyon (FRA) (e-mail: 
eulalie.courcelles@novadiscovery.com). 
C. C. is with the Department of Industrial Engineering, Alma Mater 
Studiorum - University of Bologna, 40136 Bologna IT and the Medical 
Technology Lab, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna IT 
(e-mail: cristina.curreli@unibo.it). 
N. F. is with the Biomechanics Section, Department of Mechanical 
Engineering, KU Leuven, Leuven, Belgium (e-mail: 
nele.famaey@kuleuven.be). 
L. G. is with the Division of Skeletal Biology & Engineering Research 
Center, KU Leuven, Belgium; the Biomechanics Section, Department of 
Mechanical Engineering, KU Leuven, Leuven, Belgium and the 
 
Index Terms— Context of Use, Good Simulation Practice, 
In Silico Trials.  
I. Introduction 
THE term “In Silico Trial” indicates the use of computer 
modelling and simulation to evaluate the safety and efficacy of 
a medical product, whether a drug, a medical device, or an 
advanced therapy medicinal product. The evaluation of safety 
and efficacy has historically been carried out experimentally, 
using in vitro tests, ex vivo tests, in vivo tests on animals, or in 
vivo tests on humans (clinical trials). But there are various 
reasons to consider computational models as an integral part of 
the evidence generation paradigm. In vitro and ex vivo tests can 
be time-consuming; animal experimentation is posing growing 
ethical and translational concerns; clinical trials are very 
expensive and require considerable time.  High costs of 
innovation and lengthy time-to-market translate into higher 
selling prices, and under-representation as discrimination (e.g., 
gender, age, ethnicity, rarity of the condition, wealth). In 
addition, many of these experimental methods only support 
rejecting a hypothesis, e.g. to show that a product is not safe or 
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not effective, but rarely do they provide information about how 
such a product can be made safer and more effective. 
Evidence of the safety and efficacy of a new medical product is 
necessary to obtain marketing authorisation from competent 
authorities (regulatory agencies, notified bodies, etc.), which 
every company needs before a medical product can be sold in a 
certain country.  All methodologies used to produce evidence 
of safety or efficacy must be considered appropriate by the 
competent authorities to whom the evidence is submitted.  Such 
evaluation is usually conducted by the Competent Authorities 
and is called certification or qualification (hereinafter we will 
use the generic term approval). Likewise, In Silico Trial 
methodologies must receive the necessary approval before they 
can be used. 
The first step in the regulatory approval of every new 
methodology is an accurate definition of the Context of Use 
(CoU)1. According to FDA-CDER “The CoU is a concise 
description of the drug development tool’s specified use in drug 
development”. FDA-CDRH defines CoUs as “a statement that 
fully and clearly describes the way the Medical Device 
Development Tool is to be used and the medical product 
development-related purpose of the use”. EMA defines the CoU 
as “Full, clear and concise description of the way a novel 
methodology is to be used and the medicine development 
related purpose of the use”. In the technical standard V&V 40, 
the CoU is a statement that defines “the specific role and scope 
of the computational model used to address the question of 
interest”[1]. 
In general, the approval is specific for that CoU, and therefore, 
a new approval must be granted for each new CoU. In Silico 
Trials, being a new class of methodologies, do not have a clear 
pathway for regulatory assessment and approval in many cases.  
To address this, the healthcare community is working towards 
the definition of Good Simulation Practice (GSP), which are 
quality standards that will define how to assess and approve an 
In Silico Trial methodology before it can be used to produce 
regulatory evidence on the safety and efficacy of a new medical 
product. The first step in the definition of the GSP is the 
compilation of all possible CoUs for In Silico Trials 
methodologies.  However, this list must offer a certain level of 
generalisation to be useful, hence we need an effective 
taxonomy for In Silico Trials CoUs. 
This review paper summarises the results of a consensus 
process which produced one possible taxonomy for In Silico 
Trials CoUs and a list of 46 possible CoUs, which cover all 
categories of the proposed taxonomy.  Examples of 31 CoUs 
were identified in the available literature; the remaining 15 
should, for now, be considered speculative. 
II. THE CONSENSUS PROCESS 
The Avicenna Alliance, a global non-profit organization that 
brings together healthcare stakeholders with the goal of making 
in silico medicine standard practice in healthcare, established a 
GSP Task Force in January 2020, to develop a Green Paper on 
Good Simulation Practice.  This paper will include a collection 
of experts’ recommendations that might support and help the 
future elaboration of GSP standards by standardisation bodies.  
 
1 A CoU is distinct from the Indication For Use (IFU), which specifies 
the disease/population for which the medical product is intended. 
The GSP Task Force agreed to develop the Green Paper using 
a grass-roots consensus process that would be run within a 
recently established online Community of Practice dedicated to 
In Silico Medicine and Digital Health: the In Silico World 
Community of Practice2. The membership is open to any 
individual who has a professional or educational interest in In 
Silico Medicine and Digital Health. To date, the community of 
practice provides a discussion forum to 308 global experts, 
including specialists from academia, industry, competent 
authorities, software houses, etc.  
After some preliminary activities, the working group started the 
CoU collection early April 2020. A first draft list of CoUs was 
considered too broad and unfocused. Thus, it was agreed to 
narrow the attention to only those CoUs that have regulatory 
relevance.  On the other hand, given the rapid evolution of this 
field, it was agreed to also include CoUs that are at the moment 
only speculative (e.g., for which not a single example can 
currently be provided, yet). 
The first draft of the collection was circulated in late April 
2020 and included 33 CoUs; the sixth and final version was 
circulated to the consensus group in November 2020 and 
included 46 CoUs.  The full list is provided below; where at 
least one example of that CoU could be identified in the 
literature, it is included.  The CoU without any exemplar 
reference should be considered speculative for the time being. 
III. THE TAXONOMY FOR CONTEXTS OF USE 
The regulatory process aims to provide Marketing 
Authorisation only to those medical products for which the 
applicant can demonstrate justified claims of safety and 
efficacy and/or performance.  Depending on the type of medical 
product and its risk class, such claims must be corroborated 
with evidence of safety and efficacy obtained with a set of 
controlled experiments conducted in vitro or ex vivo, in vivo on 
animals, or in vivo on humans, with multiple clinical trials 
involving progressively growing numbers of participants. The 
controlled experiments in general must be executed in a 
prescribed order, and each experiment supports the design and 
provides evidence for the authorisation of the subsequent 
experiment, or of the final Marketing Authorisation. 
In Silico Trials aim to reduce, refine, or replace these 
experiments: 
- Reduce means to reduce the number of in vitro 
experiments or those involving living subjects (animals or 
humans), their duration, or the number of experimental 
subjects (animals or humans) involved in the experiment, 
or the number of measurements performed during the 
experiment. 
- Refine means to revise the study design in order to 
eliminate or relieve the suffering of the animals involved, 
or the risks for the humans involved in the experiments; or 
to shift the experiment to non-animal species, in 
accordance with animal experimentation ethics. For in 
vitro experiments and animal experiments, refine also 
means improving the ability of the experiment to predict 
the results of the human experimentation. 
2 https://insilico.world/community/  
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- Replace means to replace entirely the experiment, 
whether in vitro, ex vivo or in vivo in animals or humans, 
with computational models and simulations. 
 Thus, the Context of Use for In Silico Trials can be 
taxonomized using the three-by-three matrix depicted in table 
1. 
IV. IN VITRO / EX VIVO EXPERIMENTS 
A. Reduce In Vitro or Ex vivo experiments  
1. In silico models can provide a framework for mapping 
measurements from one experimental setup to another. 
This can be useful when multiple measurements are 
made in earlier experiments. The model can then be used 
to guide and prioritise future experiments. Example: Ion 
channel inhibition in an expression system is integrated 
into stem cells or animal cells [2].  
2. For in vitro or ex vivo experiments aimed to support 
safety assessment, in silico models can identify the 
worst-case scenario relevant to the intended clinical use 
in the target population to be tested experimentally. 
Example: A model predicts increased blood damage of 
rotary blood pumps when used in low-flow operating 
conditions [3]. 
3. For in vitro experiments where the effect of a large 
number of parameters needs to be explored, such 
exploration can be carried out in silico, reducing the 
number of experiments required to validate the model. 
Example: An in vitro/in silico framework for off-target 
receptor toxicity of chemicals [4]. 
 
B. Refine In Vitro or Ex vivo experiments 
4. In silico models can identify/prioritise sources of 
variability to be minimized in an experimental design. 
Example: A model predicts that cell-to-cell adhesive 
heterogeneity in a tumour population influences 
Glioblastoma invasion and needs to be considered in 
in vitro experiments [5]. 
5. In silico models can identify biomarkers that best 
measure a value of interest. Example: Machine 
learning reveals serum sphingolipids as cholesterol-
independent biomarkers of coronary artery disease [6]. 
6. A specimen-specific in silico model prediction can be 
used as a surrogate biomarker in an experimental 
study, when that value of interest is difficult, risky, too 
expensive or impossible to be observed 
experimentally. Example: A computational tool that 
can simulate the behaviour of a population of cells 
cultured in a 3D scaffold [7]. 
7. In silico models can be used to support the construct 
validity of a specific biomarker, by demonstrating 
convergent validity, separation between known 
groups, and/or discriminant validity. Example: A 
model predicts that protein kinase identified as 
mediator of resistance in thyroid cancer stem cells 
after BRAF inhibitor treatment [8]. 
8. In silico models can provide evidence that supports the 
selection of drug dosage, device configuration, 
delivery mode, etc. to be used in the clinical trials. 
Example: in silico tumour model to predict responses 
of Glioblastoma cells to targeted drugs and use this 
model to stratify patients for clinical trials [9]. 
9. In silico models can confirm or refute the declared 
mechanism of action for a new medical product. 
Example: Identifying drug effects as alterations of 
cell signalling pathways through in silico modelling 
[10]. 
 
C. Replace In Vitro or Ex vivo experiments 
10. In silico models can replace in vitro or ex vivo 
experiments when it is demonstrated that they provide 
an equivalent or more realistic representation of the 
clinical conditions of use than any currently available 
in vitro or ex vivo experiment. Example: a new 
treatment for Cryptosporidiosis, after some 
preliminary results in vitro, was optimised for potency 
in silico [11]. 
 
V. ANIMAL EXPERIMENTS 
A. Reduce animal experiments 
11. Specific in silico models of a wide range of different 
animal models and breeds can better define the 
relevant animal type and size prior to in vivo testing. 
Example: an in silico methodology was used to 
TABLE I 
TAXONOMY OF THE POSSIBLE CONTEXTS OF USE OF IN SILICO TRIAL 
METHODOLOGIES.  
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effectiveness 
provided by the in 
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optimise the size and the positioning of the Realheart 
total artificial heart in bovines [12]. 
12. Where animal-specific in silico models can quantify 
certain biomarkers as accurately as in the animal 
experiment, in silico-augmented animal studies can 
reduce the number of animals required to achieve 
statistical significance. Example: Simulation of 
thrombogenicity in ventricular assist devices 
correlates with in vitro and in vivo animal studies [13]. 
13. In silico models can extrapolate the long-term results 
of a longitudinal animal experiment, reducing the 
duration of the study.  This also reduces the 
numerosity by lowering the animals lost at follow-up. 
Example: a statistical model is used to predict the 
effect of attrition (loss of animals) in longitudinal 
studies [14]. 
14. Use in silico models to interpolate intermediate results 
when the investigation requires a time-course study. 
Example: use a model to interpolate between in vivo 
microCT scans in longitudinal studies on mice, to 
reduce the x-ray exposure, which could affect the 
animal experiment [15]. 
15. In animal experiments where the effect of a large 
number of parameters needs to be explored, such 
exploration can be performed in silico, reducing the 
number of experiments required for the nonclinical 
validation of the medical product. Example: in silico 
tools for evaluating rat oral acute toxicity [16]. 
B. Refine animal experiments 
16. In preparation for a clinical trial, the use of in silico 
models can improve the translation of results from the 
animal model to humans: Example: an in silico model 
validated with animal experiments is used to optimise 
the delivery protocol and maximise efficacy in the 
development cancer preventive vaccines [17]. 
17. In silico models can be used for detailed retrospective 
evaluation of in vivo experiments based on the data 
generated in case an intervention has failed. 
18. In silico models can provide virtual control arms, 
replacing steps that involve animal suffering, such as 
sham operations. 
19. In animal models where the disease is induced 
surgically, use the animal experiment to observe the 
response to treatment in wild-type animals, and then 
use an in silico model to simulate the change in 
response when the disease is present. 
C. Replace animal experiments 
20. In silico models can replace animal experiments when 
they provide an equivalent or more realistic 
representation of the clinical conditions of use than 
any currently available animal experiment. Example: 
Human in silico drug trials demonstrate higher 
accuracy than animal models in predicting clinical 
pro-arrhythmic cardiotoxicity [18]. 
21. Combine in silico models with cell-based biological 
set-ups to obtain relevant testing conditions and map 
cellular system results to appropriate cell type, tissue 
type or organ type observations, as a means to replace 
entirely animal experimentation. Example: a recent 
review on these approaches is available [19]. 
22. In silico models can replace in vivo experiments for 
interventional training through realistic and immersive 
real-time simulation. Example: while we could not 
find direct comparisons, there are studies that use in 
silico training and other studies that use in vivo 
training on animals [20], [21]. 
 
VI. HUMAN TRIALS 
A. Reduce human experiments 
23. In silico models can determine, justify, and/or confirm 
eligibility or exclusion criteria for proper patient or 
treatment selection. Consolidate heterogeneous 
patient populations by providing in silico evidence of 
the irrelevance of potential confounding factors.  
Example: use a digital twin model to decide which 
abdominal aortic aneurysm patients need treatment.  
Such technologies can also be use to refine the 
inclusion criteria of a clinical trial [22]. 
24. Use an in silico model to enrol the right patients for a 
clinical trial and evaluate the suitability of each patient 
in detail prior to treatment. 
25. Patient-specific in silico model (a model informed 
with some quantifications made on an individual 
patient) that provides a quantification of a biomarker 
more accurately and precisely than its experimental 
quantification, reducing the number of patients 
required to achieve statistical significance. Example: 
in a clinical trial of a new thrombectomy device, the 
primary end point, the volume of saved brain tissue 
was determined using a using a machine learning 
model [23]. 
26. Extrapolate the long-term results of a longitudinal 
clinical trial, reducing the duration of the study. This 
also reduces the numerosity by lowering the patients 
lost at follow-up. 
27. Patient-specific in silico model that provides a 
quantification of a biomarker that is used as primary 
endpoint in the clinical trial; the trial is powered to 
ensure significance on the discrimination for this 
biomarker. Example: An MRI-based patient-specific 
cartilage degeneration algorithm was able to predict 
osteoarthritis (OA) progression closely to that 
observed radiographically [24]. 
28. Use a translational in silico model informed by 
preclinical experiments to inform clinical 
development decisions. Example: model based on 
cellular signalling interactions that predict the 
influence of a cytokine on the survival, duplication and 
differentiation of the CD133+ HSC/HPC subset from 
human umbilical cord blood [24]. 
29. Use Bayesian adaptive clinical trial designs, where the 
prior is provided by In Silico Trials on virtual patients 
(In Silico-Augmented Clinical Trials) to reduce the 
number of enrolled patients. Example:  A novel 
method based on the power prior for augmenting a 
clinical trial using virtual patient data is illustrated by 
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a case study of cardiac lead fracture [25]. 
30. Use In Silico-Augmented Clinical Trials to achieve 
statistical significance when there is sparsity in the 
clinical data, to include as virtual patient sub-groups 
that are difficult to recruit, or when the recruitment in 
general is difficult, as is frequently the case for rare 
diseases.      
31. Where such effects are well described and can be 
modelled, use In Silico Trials to account for response 
biases due to biological sex, gender, ethnicity, 
lifestyle, etc., thereby reducing the size of the clinical 
trial required to account for all these subgroups. 
Example:  Design of electrocardiography criteria in a 
retrospective cohort (n = 76) and then analysed in a 
validation cohort (n = 53) [26]. 
 
B. Refine human experiments 
32. In silico models that provide virtual control arms, to 
avoid enrolling healthy volunteers, replace placebo 
arms when the ethics of non-treatment is questionable, 
or when the control arm involves unnecessary risks for 
the participants. Example: A statistical model for a 
virtual control arm for chemotherapy [27]. 
33. Enrich existing clinical trial results by simulating 
unexplored scenarios (e.g., additional regimen) and/or 
predicting an additional outcome.  Example: find in 
silico that a specific risk (e.g. restenosis) can be 
reversed spontaneously over time, in tissue-
engineered vascular graft for paediatric use [28]. 
34. Shorten the learning curve for a specific intervention 
through in silico training.  Example: Use of in silico 
training for craniofacial, hand, microvascular, and 
aesthetic surgery [29]. 
35. In Silico Trials conducted on virtual populations to 
define clinical trial inclusion and exclusion criteria. 
Example: In silico trials for acute ischemic stroke 
through virtual clot and patient populations [30]. 
36. In silico models can identify the root cause of failures 
that may occur under broad clinical use. Example: A 
model predicts the potentially differential effects of 
atrial dilation vs. hypertrophy on the ECG P-wave 
[31]. 
37. The inclusion of virtual patients to enrich existing 
clinical trials with In Silico Trials for underserved or 
underrepresented populations (e.g., paediatric, rare 
disease) and to accelerate clinical trials when 
enrolment is challenging. 
38. In Silico Trials that support Post-Marketing 
Surveillance by using in silico evidence to provide 
accelerated marketing authorisation. This approach is 
constrained by a tight post-marketing surveillance, 
where outcomes and adverse effects must not deviate 
from the statistical distribution predicted in silico. 
 
C. Replace human experiments 
39. In Silico Trials used as surrogate human experiments 
when these are impossible to perform. 
40. In Silico Trials to replace phase II clinical trials to 
evaluate dose-response in patients. Example: in silico 
evaluation of ivabradine efficacy in patients with 
angina pectoris [32]. 
41. In Silico Trials for phase jumping. For example, the 
use of phase II clinical trial results to predict the results 
of a phase III clinical trial, as evidence to support the 
request for conditional marketing approval (post-
marketing phase III trial). 
42. In Silico Trials of a product that already received 
marketing authorisation, to validate relabelling, 
repurposing, retargeting, minor design modifications, 
etc.  This includes also relabelling for paediatric use. 
43. Safety In Silico Trials to assess possible interactions 
between multiple treatments. 
44. Efficacy In Silico Trials of multi-product treatments. 
45. In Silico-only trials for lower risk class medical 
devices. 
46. In Silico Trials for in vitro diagnostic medical devices. 
 
VII. CONCLUSIONS 
This review paper summarised the results of a consensus 
process which produced one possible taxonomy for In Silico 
Trials CoUs and a list of 46 possible CoUs, which cover all 
categories of the proposed taxonomy. 
The authors believe that the consensus on possible Contexts 
of Use as the one proposed here is a first essential step in the 
development of Good Simulation Practice for In Silico Trials. 
Such a list allows for discussions on the regulatory science 
behind the use of In Silico Trials that are grounded into a 
concrete spectrum of use cases. 
The development of a Good Simulation Practice standard is 
a challenging endeavour, for technical and cultural reasons.  
The community of practice that the authors represent plans to 
modulate the risks by developing first a consensus position 
paper that attempts to address the most complex aspects of such 
standard and open it for discussion with experts working at 
major regulatory agencies, so to get as close as possible to what 
could become tomorrow an internationally adopted standard. 
Although we have collected 46 different use cases, and many 
more could be defined at a lower level, the same principle of 
reduce, refine, replace can be applied to the generation of 
regulatory evidence that is typically done using in vitro, animal, 
or human experimentation. 
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